// App-Quantinova.ai

: Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes

Researchers

Presenter

  • Mark Dransfield

Principal Investigators

  • David Halpin

  • Helen Barnacle

  • Ruby Birk

  • Noushin Brealey

  • Chang-Qing Zhu

  • David Lipson

Medical Centers

  • University of Alabama at Birmingham, Birmingham, Alabama, United States

  • Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • GSK, Uxbridge, United Kingdom

  • CSL Behring, King of Prussia, United States of America

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Exostosin Glycosyltransferase 1

Drug/Treatment

  • Umeclidinium

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved